Sun Pharma Q4FY26 PAT rose 26.2% YoY to ₹2,714 crore, while the board declared a final dividend of ₹5 per share for FY26.


By Dalal Street Investment Journal (DSIJ)

Summary :

 

Sun Pharmaceutical Industries reported Q4FY26 revenue growth of 13.6% YoY to ₹14,611.79 crore, while PAT increased 26.2% YoY to ₹2,714.03 crore. FY26 revenue rose 11.9% and PAT stood at ₹11,479.42 crore. The board recommended a final dividend of ₹5 per share, taking total FY26 payout to ₹16 per share.

Sun Pharma Share Price Falls 2.47% After Q4FY26 Results

On Thursday, May 22, 2026, Sun Pharma share price dropped by 2.47%, closing at ₹1,844.60, with the lowest level during the day being ₹1,833.10, after having opened at ₹1,903. In total, 36.1 lakhs shares traded today as opposed to the 30 day average of 48.6 lakhs. This decrease happened even though the company had reported some impressive figures for the Q4FY26 quarter.

Q4FY26: Quarterly Performance of Sun Pharma

For the quarter ended March 31, 2026, Sun Pharma reported consolidated revenue from operations of ₹14,611.79 crore, up 13.6% YoY from ₹12,958.88 crore in Q4FY25 and down 5.8% QoQ from ₹15,520.54 crore in Q3FY26. Other income for the quarter stood at ₹458.50 crore, taking total income to ₹15,070.29 crore compared to ₹13,571.71 crore in Q4FY25 and ₹16,099.38 crore in Q3FY26.

Total expenses for the quarter stood at ₹11,518.95 crore against ₹9,955.68 crore in Q4FY25 and ₹11,382.74 crore in Q3FY26.

EBITDA for the quarter came in at ₹3,954.20 crore, up 6.4% YoY, with an EBITDA margin of 27.1%. R&D investment for the quarter stood at ₹975.70 crore, representing 6.7% of sales.

PBT stood at ₹3,551.34 crore, up 9.1% YoY from ₹3,254.35 crore in Q4FY25 and down 15.9% QoQ from ₹4,227.16 crore in Q3FY26. PAT attributable to shareholders for the quarter came in at ₹2,714.03 crore, up 26.2% YoY from ₹2,149.88 crore in Q4FY25 and down 19.4% QoQ from ₹3,368.81 crore in Q3FY26.

Segment Performance in Q4FY26

India formulations sales for Q4FY26 stood at ₹4,835.90 crore, up 14.8% YoY, accounting for 33.2% of total consolidated sales. Sun Pharma retained its position as India's No. 1 pharma company, with market share increasing from 8.1% to 8.4% as per the Pharmarack MAT March 2026 report. The company ranks No. 1 by prescriptions in 11 different doctor categories and launched 11 new products during the quarter.

US formulations sales for Q4FY26 stood at $459 million, lower by 1.1% YoY, accounting for approximately 28.8% of total consolidated sales. Innovative Medicines continued to grow within the US segment, partially offsetting the decline in the generics business.

Global Innovative Medicines sales for Q4FY26 came in at $354 million, up 20.1% YoY, accounting for 22.2% of sales — a segment that has now crossed the $1 billion annual revenue mark for the first time in FY26.

Emerging Markets formulations sales were $306 million for the quarter, up 17.4% YoY, accounting for 19.2% of consolidated sales. Rest of World formulations sales were $220 million, up 10% YoY, accounting for 13.8% of consolidated sales.

External API sales for the quarter stood at ₹673.90 crore, up 26.4% YoY.

Sun Pharma Adv Res Co Ltd

Trade

209.7729.44 (16.32 %)

Updated - 22 May 2026
214.00day high
DAY HIGH
179.82day low
DAY LOW
32264158
VOLUME (BSE)

Sun Pharma Dividend Declaration of ₹5

The Board of Directors recommended a final dividend of ₹5 per equity share on a face value of ₹1 each for FY26, subject to approval by shareholders at the 34th Annual General Meeting. This is in addition to the interim dividend of ₹11 per share already paid during FY26, taking the total dividend for the year to ₹16 per share — the same as FY25.

Full Year FY26 Performance of Sun Pharma

For the full year ended March 31, 2026, Sun Pharma posted consolidated revenue from operations of ₹58,462.01 crore, up 11.9% on an annual basis from ₹52,578.44 crore in FY25. Other income for the year stood at ₹1,971.72 crore, taking total income to ₹60,433.76 crore compared to ₹54,543.48 crore in FY25.

Total expenses for FY26 stood at ₹44,007.40 crore against ₹40,113.50 crore in FY25.

EBITDA for FY26 came in at ₹17,731.40 crore, up 16.1% on an annual basis, with EBITDA margin expanding to 30.3% from 27.9% in FY25.
PBT for the year stood at ₹15,118.88 crore, up 9.9% on an annual basis from ₹13,752.13 crore in FY25. PAT attributable to shareholders for FY26 came in at ₹11,479.42 crore, up 5% on an annual basis from ₹10,929.04 crore in FY25.

For the full year, Global Innovative Medicines sales stood at $1,420 million, up 16.8% YoY and accounting for 20.7% of sales. US formulations full year sales were $1,904 million. Emerging Markets full year sales stood at $1,265 million, up 13.6% YoY. Rest of World full year sales were $969 million, up 14.4%. India formulations full year sales stood at ₹19,290.40 crore, growing 14% annually.

Management Commentary

Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Limited, said the full year performance reflects several significant achievements. He noted that the company's 0.3 percentage point gain in the India market is its highest since the Ranbaxy acquisition. He added that the US Innovative Medicines business has surpassed $1 billion in revenues, and that the recently announced Organon acquisition is expected to further accelerate Sun's transformation into a leading global pharmaceutical company.

R&D Update

Sun Pharma's R&D pipeline includes five novel entities currently in the clinical stage. In the US market, the company has approved ANDAs for 552 products, with filings for 122 ANDAs awaiting US FDA approval, including 28 tentative approvals. During the quarter, 7 ANDAs were filed and approval was received for 2 ANDAs. Sun's portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval.

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is India's largest pharmaceutical company and the fourth-largest specialty generic pharmaceutical company in the world. The company manufactures and markets a large basket of pharmaceutical formulations as prescription and over-the-counter products across India, the US, and more than 100 countries. Its businesses span branded generics, generics, complex generics, and innovative medicines across dermatology, ophthalmology, oncology, and other therapy areas. Sun Pharma is listed on the BSE and NSE and is headquartered in Mumbai.

 

Source: Dalal Street Investment Journal (DSIJ), TradingView, NSE, BSE

 

About the Author

SEBI Registered Research Analyst (INH000006396).


Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

Published Date : 22 May 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text